By Thomas Scharnitz, MD Held as a virtual event this year due to the COVID-19 pandemic, the 29th Congress of the EADV hosted nearly 11,000 attendees logging in from all over the world. Psoriasis played an important role in the EADV agenda, according to conference planners, in recognition that the disease affects 2-3% of the world's population. The EADV virtual congress featured sessions on psoriasis genetics and pathophysiology as well as presentations on promising therapies, from "classical treatments to small molecules," psoriasis and pregnancy, biologics and the treatment of cardiovascular inflammation, and more. The following are summaries of the EADV sessions with a focus on psoriasis.
Latest news Video Series on IPC’s Psoriasis Severity ReclassificationMarch 30, 2021Learn how psoriasis severity is currently measured and why a change is necessary, how IPC organized the Delphi process that was used to redefine severity classification, implications and effects the output has on psoriasis treatment providers and psoriasis patients, and ultimately how patients will benefit from this endeavor. Janssen Phase-3 TREMFYA® Clinical TrialMarch 29, 2021Janssen Pharmaceutical Companies of Johnson & Johnson published the long-term data of the third phase of the DISCOVER-2a study. Sun Pharma Phase-3 ILUMYA® Clinical TrialMarch 28, 2021Sun Pharmaceutical Industries Inc. announces results from their five-year Phase-3 efficacy and safety clinical trial for ILUMYA®(tildrakizumab-asmn) based on a pooled analysis of the ReSURFACE 1 and ReSURFACE 2 extension. Update on PsoProtect Registry DataMarch 17, 2021Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1002 cases. More News
Stay informed Join the email list to receive the latest information on psoriasis meetings, manuscripts and research. SUBSCRIBE